Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab vs Carboplatin/Gemcitabine/Bevacizumab in Patients with Recurrent Ovarian Cancer

Conference Correspondent  - ESMO 2018

For patients with recurrent ovarian cancer suitable for platinum-based retreatment, standard platinum-containing treatments include carboplatin/gemcitabine/bevacizumab (CG-BEV) and carboplatin/pegylated liposomal doxorubicin (CD). CG-BEV has been shown to significantly increase progression-free survival (PFS) over CG alone,1 whereas CD has one of the best therapeutic indices for platinum-sensitive recurrent ovarian cancer that is suitable for retreatment.2 Here, Pfisterer et al report the results of a prospective, randomized, phase 3 trial, designed to evaluate whether CD is superior to CG when given in combination with BEV with investigator-determined PFS as the primary objective.3

Patients with recurrent ovarian cancer suitable for platinum-based retreatment were randomized to receive standard CG-BEV (n = 337) or experimental CD-BEV (n = 345). Secondary objectives included overall survival, biological PFS by serum CA125 levels, quality of life, safety, and tolerability. The trial was designed to have 80% power to show a 26.6% change in PFS (hazard ratio [HR], 0.79; 564 PFS events). Patients were stratified by presence of residual tumor, platinum-free interval, and prior antiangiogenic treatment.

At the time of data cutoff, 571 events had occurred. Of the included patients, 87.4% had serous histology, 83.1% were high grade, and 41.5% had previously received BEV as part of first-line treatment. CG-BEV was associated with 359 (53.3%) serious adverse events versus 314 (46.7%) for CD-BEV (P = .083). Median PFS in the CG-BEV arm was 11.7 months (95% CI [confidence interval], 11.1-12.8) versus 13.3 months (95% CI, 11.7-14.3) in the experimental CD-BEV arm (HR, 0.80; 95% CI, 0.68-0.96; P = .0128). For patients who had received previous antiangiogenic treatment (n = 309), median PFS was 10.1 months (95% CI, 8.5-11.2) for CG-BEV versus 11.3 months (95% CI, 10.1-13.8) for CD-BEV (HR, 0.73; 95% CI, 0.57-0.94; P = .0126).

Experimental CD-BEV provided a significant PFS improvement compared with CG-BEV in patients with recurrent ovarian cancer suitable for platinum-based retreatment. A significant PFS improvement was also seen in the subgroup of patients who had received previous antiangiogenic treatment. Furthermore, CD-BEV was associated with fewer serious adverse events, including a 45% reduction in grade ≥3 neutropenia. These data suggest that CD-BEV could be an important addition to the therapeutic options in these patients.


References

  1. Aghajanian C, et al. J Clin Oncol. 2012;30(17):2039-2045.
  2. Mahner S, et al. Eur J Cancer. 2015;51(3):352-358.
  3. Pfisterer J, et al. ESMO 2018. Abstract 933O.
Related Items
A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
A Phase 1b and Randomized Phase 2 Trial of Pazopanib with or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
The Efficacy of Apatinib Treatment for Advanced Ovarian Cancer After Second-Line Chemotherapy Failure
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cancer
Conference Correspondent  published on October 22, 2018 in ESMO 2018
Maintenance Olaparib Following Platinum-Based Chemotherapy in Newly Diagnosed Patients with Advanced Ovarian Cancer and a BRCA1/2 Mutation: Results from the Phase 3 SOLO1 Trial
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 2 Trial of Combination Nivolumab and Bevacizumab in Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
Association of PD-L1 Expression with Clinical Response to Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer
Conference Correspondent  published on October 21, 2018 in ESMO 2018
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
Conference Correspondent  published on October 20, 2018 in ESMO 2018
Last modified: October 19, 2018